Back in August 2015, I wrote about an article in the journal Nature on some interesting new discoveries about the role of the hormone progesterone in hormone receptor-positive breast cancer.
The research suggested that adding progesterone to standard treatment with tamoxifen or an aromatase inhibitor could increase the effectiveness of treatment for this subtype of breast cancer, while possibly also lowering toxicity.
Cancer Research UK reports that these findings are now going to be investigated in three clinical trials that are set to begin. Continue reading
What’s exciting in cancer research right now? In this post, I’ll review several of the most interesting cancer research stories that have been in the news this fall.
Many of us are interested in making donations in support of cancer research. But figuring out which organizations will make the most effective use of our contributions isn’t always an easy task. This post is the second in a series in which we’re looking at individual charities that focus primarily on cancer research.
A recent study got me thinking again about one of the central issues around clinical trials — why don’t more of us participate?
These days the media hype around cancer “breakthroughs” seems to have reached a new high. There have been advances, but there is still such a long way to go before we can say we have real breakthroughs that are changing the outlook for most patients.
The title of this book certainly got my attention and made me curious about what the author had to say. Is the “death” of cancer, or the end of cancer as a deadly disease, really possible? Can we actually win the war on cancer, which has been pronounced a failure by many?
We’ve heard a lot in the news over the last year about how researchers are working to develop a blood test to detect cancer, sometimes referred to as a “liquid biopsy”.
Looking back over the past year, what were some of the big things we learned that contribute to the progress that’s being made against cancer?
